Immuno-chemotherapy of advanced colorectal cancer with alpha-2a interferon and 5-fluorouracil. Immunopharmacological studies. 1991

R De Filippi, and G Cucchiara, and S P Prete, and S Marini, and F Ricci, and C Nunziata, and M Turriziani, and E Bonmassar, and M P Fuggetta, and L De Vecchis
Department of Experimental Medicine and Biochemical Sciences, 2nd University of Rome, Italy.

Twelve patients with metastatic colorectal cancer received alternating cycles of low immunomodulating doses of alpha-IFN + 5-Fluorouracil (5-FU) or 5-FU alone. Hematological, biochemical and physical evaluation showed that both treatment cycles were well tolerated. However, transient fever and moderate flu-like symptoms were observed following alpha-IFN administration. Treatment with 5-FU alone produced long-lasting inhibition of CD8+ T lymphocytes, but did not depress NK activity (NKA). Combined treatment with alpha-IFN produced a short-term increase of NKA and antagonized the effect of 5-FU on CD8+ cells on day 5 of the cycle. Parallel studies on in vitro models showed antiproliferative effects of 5-FU on PHA-stimulated MNC and confirmed the preferential inhibition of CD8+ cells. Pretreatment with alpha-IFN did not reverse the effect of 5-FU on CD8+ lymphocytes, but partially protected MNC from the toxic effects of the drug. This was presumably due to the cytostatic effects induced by alpha-IFN on MNC before exposure to the cycle-specific antineoplastic agent. This investigation suggests that alpha-IFN could play a positive role in immuno-chemotherapy of colorectal cancer through multiple mechanisms not entirely related to direct antitumor effects of the agent.

UI MeSH Term Description Entries
D007113 Immunity, Innate The capacity of a normal organism to remain unaffected by microorganisms and their toxins. It results from the presence of naturally occurring ANTI-INFECTIVE AGENTS, constitutional factors such as BODY TEMPERATURE and immediate acting immune cells such as NATURAL KILLER CELLS. Immunity, Native,Immunity, Natural,Immunity, Non-Specific,Resistance, Natural,Innate Immune Response,Innate Immunity,Immune Response, Innate,Immune Responses, Innate,Immunity, Non Specific,Innate Immune Responses,Native Immunity,Natural Immunity,Natural Resistance,Non-Specific Immunity
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D007963 Leukocytes, Mononuclear Mature LYMPHOCYTES and MONOCYTES transported by the blood to the body's extravascular space. They are morphologically distinguishable from mature granulocytic leukocytes by their large, non-lobed nuclei and lack of coarse, heavily stained cytoplasmic granules. Mononuclear Leukocyte,Mononuclear Leukocytes,PBMC Peripheral Blood Mononuclear Cells,Peripheral Blood Human Mononuclear Cells,Peripheral Blood Mononuclear Cell,Peripheral Blood Mononuclear Cells,Leukocyte, Mononuclear
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

R De Filippi, and G Cucchiara, and S P Prete, and S Marini, and F Ricci, and C Nunziata, and M Turriziani, and E Bonmassar, and M P Fuggetta, and L De Vecchis
August 1995, Cancer,
R De Filippi, and G Cucchiara, and S P Prete, and S Marini, and F Ricci, and C Nunziata, and M Turriziani, and E Bonmassar, and M P Fuggetta, and L De Vecchis
December 1993, Cancer,
R De Filippi, and G Cucchiara, and S P Prete, and S Marini, and F Ricci, and C Nunziata, and M Turriziani, and E Bonmassar, and M P Fuggetta, and L De Vecchis
August 1990, Tumori,
R De Filippi, and G Cucchiara, and S P Prete, and S Marini, and F Ricci, and C Nunziata, and M Turriziani, and E Bonmassar, and M P Fuggetta, and L De Vecchis
January 1995, European journal of cancer (Oxford, England : 1990),
R De Filippi, and G Cucchiara, and S P Prete, and S Marini, and F Ricci, and C Nunziata, and M Turriziani, and E Bonmassar, and M P Fuggetta, and L De Vecchis
December 1990, Cancer,
R De Filippi, and G Cucchiara, and S P Prete, and S Marini, and F Ricci, and C Nunziata, and M Turriziani, and E Bonmassar, and M P Fuggetta, and L De Vecchis
September 1996, British journal of cancer,
R De Filippi, and G Cucchiara, and S P Prete, and S Marini, and F Ricci, and C Nunziata, and M Turriziani, and E Bonmassar, and M P Fuggetta, and L De Vecchis
July 1999, Anti-cancer drugs,
R De Filippi, and G Cucchiara, and S P Prete, and S Marini, and F Ricci, and C Nunziata, and M Turriziani, and E Bonmassar, and M P Fuggetta, and L De Vecchis
April 1990, Cancer research,
R De Filippi, and G Cucchiara, and S P Prete, and S Marini, and F Ricci, and C Nunziata, and M Turriziani, and E Bonmassar, and M P Fuggetta, and L De Vecchis
September 1998, Anti-cancer drugs,
R De Filippi, and G Cucchiara, and S P Prete, and S Marini, and F Ricci, and C Nunziata, and M Turriziani, and E Bonmassar, and M P Fuggetta, and L De Vecchis
March 1995, Cancer,
Copied contents to your clipboard!